Aspire BioPharma, Inc. (ASBP) - Net Assets
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has net assets worth $-11.47 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.40 Million) and total liabilities ($13.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Aspire BioPharma, Inc. for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.47 Million |
| % of Total Assets | -477.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.32 |
Aspire BioPharma, Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Aspire BioPharma, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Aspire BioPharma, Inc. assets under control for the complete picture of this company's asset base.
Annual Net Assets for Aspire BioPharma, Inc. (2021–2024)
The table below shows the annual net assets of Aspire BioPharma, Inc. from 2021 to 2024. For live valuation and market cap data, see how much is Aspire BioPharma, Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.54 Million | -107.87% |
| 2023-12-31 | $19.58 Million | -93.23% |
| 2022-12-31 | $289.07 Million | +60856138.32% |
| 2021-12-31 | $-475.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aspire BioPharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 275175800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $169.99K | % |
| Other Components | $1.07 Million | % |
| Total Equity | $-1.54 Million | 100.00% |
Aspire BioPharma, Inc. Competitors by Market Cap
The table below lists competitors of Aspire BioPharma, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
General Shopping e Outlets do Brasil S.A.
SA:GSHP3
|
$1.07 Million |
|
The Alumasc Group plc
LSE:ALU
|
$1.07 Million |
|
Queste Communications Ltd
AU:QUE
|
$1.07 Million |
|
X3 Holdings Co Ltd
NASDAQ:XTKG
|
$1.07 Million |
|
Story-I Ltd
AU:SRY
|
$1.07 Million |
|
Grupo Famsa S.A.B. de C.V
MX:GFAMSAA
|
$1.06 Million |
|
LUNGLIFE AI INC. DL-0001
F:9H4
|
$1.06 Million |
|
Marksmen Energy Inc
V:MAH
|
$1.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aspire BioPharma, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,579,064 to -1,540,088, a change of -21,119,152 (-107.9%).
- Net loss of 12,537,000 reduced equity.
- Share repurchases of 13,781,323 reduced equity.
- New share issuances of 257,645 increased equity.
- Other factors increased equity by 4,941,526.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.54 Million | -814.04% |
| Share Repurchases | $13.78 Million | -894.84% |
| Share Issuances | $257.64K | +16.73% |
| Other Changes | $4.94 Million | +320.86% |
| Total Change | $- | -107.87% |
Book Value vs Market Value Analysis
This analysis compares Aspire BioPharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.00 | $0.21 | x |
| 2022-12-31 | $2.28 | $0.21 | x |
| 2023-12-31 | $0.26 | $0.21 | x |
| 2024-12-31 | $-0.05 | $0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aspire BioPharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (5.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.43K |
| 2022 | 1.16% | 0.00% | 0.00x | 1.04x | $-25.57 Million |
| 2023 | 22.80% | 0.00% | 0.00x | 1.02x | $2.51 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.38 Million |
Industry Comparison
This section compares Aspire BioPharma, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aspire BioPharma, Inc. (ASBP) | $-11.47 Million | 0.00% | N/A | $1.07 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for subl… Read more